Form 8-K Editas Medicine, Inc. For: Nov 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Chardan Capital Markets Reiterates Buy Rating on Editas Medicine (EDIT)
November 5, 2024 4:19 PM ESTChardan Capital Markets analyst Geulah Livshits reiterated a Buy rating and $12.00 price target on Editas Medicine (NASDAQ: EDIT).
The analyst comments "EDIT (Buy, PT $12): 3Q24 Results; Reni-cel Data at ASH; In Vivo Updates in 1Q25. On 4 November, Editas Medicine reported 3Q24 results and... More
Editas Medicine (EDIT) PT Lowered to $5 at Barclays
November 5, 2024 5:23 AM ESTBarclays analyst Gena Wang lowered the price target on Editas Medicine (NASDAQ: EDIT) to $5.00 (from $7.00) while maintaining a Equalweight rating.
The analyst comments "Key takeaways. 3Q24 PR was incremental following recent strategic update (see EDIT - Strategic update mixed, 10/22/2024). Reni-cel (EDIT-301): Mgmt. reiterated... More
Editas Medicine (EDIT) PT Lowered to $8 at Truist Securities
November 4, 2024 12:25 PM ESTTruist Securities analyst Joon Lee lowered the price target on Editas Medicine (NASDAQ: EDIT) to $8.00 (from $12.00) while maintaining a Buy rating.
The analyst comments "3Q24: No surprises on the quarter post recent announcements (our prior takes - HERE and HERE). EDIT... More
